Critical inputs
Regional capacity for reagents, oligonucleotides, enzymes, calibrators and consumables whose interruption stops testing.
Ideas
Diagnostics Sovereignty
Modern health systems can be clinically advanced and still depend on reagents, instruments, software, data and servicing controlled elsewhere.
Sovereignty is not self-sufficiency
It does not require a country or region to manufacture everything itself. It requires sufficient control over critical reagents, consumables, instruments, servicing, data, reference resources, quality systems, regulation and supply resilience to preserve diagnostic capability and engage external suppliers from a position of capability rather than necessity.
Precision medicine may be the most ambitious use of diagnostics, but sovereignty begins with something more basic: ensuring that the tests a health system depends on continue to work when supply chains are disrupted.
The diagnostic sovereignty stack
Sovereignty is a system of connected capabilities. Manufacturing without regulation, data without validation, or procurement without industrial strategy leaves the underlying dependency intact.
Instruments and servicing
Maintenance, calibration, spare parts and technical support that keep diagnostic platforms operational throughout their working life.
Supply and logistics
Cold-chain infrastructure, strategic inventories, alternative routes and supplier redundancy for routine operations and crises.
Quality and regulation
Quality systems, domestic registration pathways, post-market oversight and regional recognition that make locally produced diagnostics credible and usable.
Data and reference resources
Population-specific genomic references, health data, algorithms and governance capable of giving diagnostic results local clinical meaning.
Biobanks and cohorts
Representative samples, accessible validation cohorts and governance that allow products to be developed and proven for the populations they will serve.
Procurement and market access
Anchor demand, intelligent local-content rules and regional market access that turn capability into a commercially sustainable industry.
Talent and capital
Industrial, regulatory, clinical and commercial expertise supported by capital patient enough to build regulated capability over time.
Four strategic choices
Not every product should be manufactured locally. The policy task is to decide deliberately where control matters and how each remaining dependency will be managed.
Build
Create domestic or regional capability where an input is critical, difficult to substitute and capable of generating cumulative industrial knowledge.
Partner
Use technology transfer, joint ventures and specialist partnerships when external expertise accelerates capability without preserving permanent dependence.
Diversify
Maintain multiple suppliers, jurisdictions and transport routes for inputs that are strategically important but widely available.
Buffer
Stockpile or reserve inputs that are essential during disruption but neither economical nor strategically useful to manufacture locally.
Questions shaping this territory
What I am trying to understand
I am particularly interested in how these pathways differ from one setting to another, and in the practical choices required to move from dependency towards greater resilience.
- Which capabilities are strategically essential?
- Where does localisation create resilience rather than theatre?
- How can a country or region build diagnostic resilience from its particular starting point, advantages, weaknesses and ambitions?
Places represented
Geographic perspectives within this idea territory.
Selected writing
A curated route into the central arguments, rather than a chronological dump.
Magnificent Hospitals, Empty Supply Chains: The case for diagnostic sovereignty in the Gulf
Published on Linkedin on April 5, 2026 A simple blood count is not a glamorous, high-tech, innovation-driven precision medicine, AI-powered solution. It is not the next shiny thing that makes investors and bureaucrats alike very excited. Yet every hospital in the Gulf runs hundreds, maybe thousands of them every day. Haematology panels, biochemistry screens, urine…
Read →The Plasticware Paradox
A Blackout, Toilet Paper, and GCC Diagnostics How the Gulf exports the raw material for molecular medicine, and imports every finished piece of it The Gulf Cooperation Council (GCC) has invested heavily in genomics, cancer care, and national screening programmes, but the region’s diagnostics manufacturing base remains thin. This essay argues that single-use laboratory plasticware…
Read →Small Is Better: Why the Gulf’s Diagnostics Sovereignty Moment Demands the Right Architecture
A few years ago, as I was exploring relocating my company to a Gulf country, I sat with the innovation lead of a regional development programme. He was visibly excited as he described how a major diagnostics multinational had committed to building a presence in his country: investment, jobs, a regional hub. The whole language…
Read →Reflections on BGI’s Gulf Partnerships: Localisation Is Not Sovereignty
As the Strait of Hormuz crisis intensifies and persists, major container lines have suspended or rerouted Gulf calls around the Cape of Good Hope, adding ten to fourteen days to deliveries of medical devices, consumables, and diagnostic inputs. Freight and insurance costs spiked. Airspace restrictions compounded the disruption: medical and humanitarian supplies including IV fluids,…
Read →